AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
AngioDynamics reported record fiscal Q4 2026 revenue of $86.6 million, up 8.0% year-over-year on a pro forma basis, fueled by a 16.7% increase in Med Tech sales to $41.8 million. Full-year fiscal 2026 revenue grew 9.4% to $320.2 million, with Med Tech revenue rising 18.4% to $150.0 million, driving full-year adjusted EBITDA of $13.2 million and a debt-free balance sheet with $53.9 million in cash.
Key figures
- Revenue
- 86600000
- Guidance
- FY2027 Net Sales $336.0M - $341.0M; Med Tech Net Sales Growth 12% – 15%; Adjusted EBITDA $13.0M - $16.0M; Adjusted EPS ($0.29) – ($0.24)
- Revenue Yoy
- 8.0%
- Fy revenue
- 320200000
- Cash balance
- 53900000
- Fy revenue yoy
- 9.4%
- Gross margin fy
- 54.6%
- Gross margin q4
- 54.0%
- Med tech fy sales
- 150000000
- Med tech q4 sales
- 41800000
- Adjusted ebitda fy
- 13200000
- Adjusted ebitda q4
- 3300000
- Med tech fy growth
- 18.4%
- Med tech q4 growth
- 16.7%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.